An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Sitravatinib (Primary)
- Indications Breast cancer; Cancer; Gastric cancer; Liposarcoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Mirati Therapeutics
Most Recent Events
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021.
- 07 Jun 2021 Status changed from recruiting to active, no longer recruiting.